BCAB250117P5000
- 0.00
- 0.000.00%
BioAtla Newsroom
12 Health Care Stocks Moving In Friday's Pre-Market Session
BioAtla Prices Registered Direct Offering of 9.7 Million Shares for Expected Gross Proceeds of $9.2 Million
BioAtla Highlights Advancements in CAB Cancer Therapy
Express News | BioAtla Announces $9.2M Registered Direct Offering Of 9,679,158 Shares At $1.19/Share
Express News | Bioatla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points
Insiders Give Up US$66k As BioAtla Stock Drops To US$1.31
BioAtla Presents Data on Mecbotamab Vedotin in Advanced NSCLC
BioAtla Presented Data Characterizing Mutated KRAS Genotype And Clinical Outcomes In Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, A CAB-AXL-ADC, At The IASLC 2024; 1-Year OS Was 58% For Patients With NSCLC Expressing MKRAS Versus 23%...
Express News | Bioatla Presented Data Characterizing Mutated Kras Genotype and Clinical Outcomes in Patients With Advanced Nsclc Treated With Mecbotamab Vedotin (Mec-V), a Cab-Axl-ADC, at the Iaslc 2024 Hot Topic in Basic & Translational Science Meeting
Express News | BioAtla Shares Are Trading Lower. The Stock May Be Reacting to the Scion Asset Management 13F Filing Disclosing an Exit From Their Position in the Company
Express News | Scion Asset Management 13F Shows Exited Position In Hudson Pacific Properties, Previously Holding 1,144,435 Shares; Exited Position In BioAtla, Previously Holding 633,959 Shares
BioAtla Analyst Ratings
H.C. Wainwright Downgrades BioAtla(BCAB.US) to Hold Rating
BioAtla Downgraded to Neutral From Buy at H.C. Wainwright
JMP Securities Maintains BioAtla(BCAB.US) With Buy Rating, Maintains Target Price $5
BioAtla: Strong Financials and Promising Clinical Progress Drive Buy Rating
BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript Summary
BioAtla Reports Q3 2024 Financial Results and Clinical Advances
BioAtla | 10-Q: Q3 2024 Earnings Report
BioAtla Reports Q3 EPS (22c), Consensus (36c)